<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022967</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12372 MODERATO</org_study_id>
    <nct_id>NCT04022967</nct_id>
  </id_info>
  <brief_title>ANRS 12372 MODERATO Study</brief_title>
  <acronym>MODERATO</acronym>
  <official_title>Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) in West and Central African HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted
      in West and Central Africa (Cameroon, Côte d'Ivoire, Burkina Faso).

      HIV-1 infected adults receiving first line ART with TDF+XTC+EFV virologically suppressed will
      be recruited and followed during 100 weeks.

      The objective is to assess the non-inferiority of a strategy consisting of switching to a
      dual maintenance therapy (DTG+ 3TC or ATV/r+3TC), comparing to WHO standard first line
      regimen (TDF+3TC+EFV), in terms of virological success at 96 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In HIV-1 infected adults receiving first line ART with TDF+XTC+EFV virologically suppressed
      (viral load &lt; detection limit of the technique used) for at least two years: to assess the
      non-inferiority of a strategy consisting of switching to a dual maintenance therapy (DTG+ 3TC
      or ATV/r+3TC), comparing to WHO standard first line regimen (TDF+3TC+EFV), in terms of
      virological success at 96 weeks, in Cameroon, Côte d'Ivoire and Burkina Faso.

      This is a trial including two strategies (dual maintenance therapy and triple reference
      therapy) and three ART regimens (DTG+3TC and ATV/r+3TC used in the maintenance strategy and
      TDF+3TC+EFV used in the reference strategy).

      The primary analysis will compare the two strategies. Secondary analyses will compare the
      three ART regimens two by two.

      In order to make these secondary analyses possible, participants will be randomly assigned,
      at inclusion, to each of the three ART regimens (arm 1: DTG+3TC; arm 2: ATV/r+3TC; arm 3:
      TDF+3TC+EFV). The maintenance strategy will include arm 1 and 2. The reference strategy will
      include arm 3

      Number of participants : 600 (200 in each ART regimen, ie 400 in the dual maintenance therapy
      strategy and 200 in the triple therapy reference strategy)

      The primary endpoint is treatment success, as defined by using the FDA snapshot algorithm :
      patients who are still continuing the assigned strategy and whose last available plasma HIV-1
      RNA in the the window analysis (90 to 102 weeks) is &lt;50 copies/ml at the end of the window
      analysis (90 to 102 weeks)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The treatment success</measure>
    <time_frame>90 to 102 weeks</time_frame>
    <description>The proportion of patients who are still continuing the assigned strategy and whose last available plasma HIV-1 RNA in the the window analysis is &lt;50 copies/ml at the end of the window analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure combined endpoint</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Percentage of participants who reach the following combined endpoint : &quot;new drug-resistant resistance mutations observed&quot;, &quot;decline of at least 20% in creatinine clearance&quot; and &quot;occurrence of at least one grade 3-4 neuropsychiatric disorder&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of plasma HIV-1 RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological success</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of the percentage of participants with virological success (VL&lt; 50 copies/Ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 lymphocyte</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of CD4 lymphocyte absolute count and percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure and new resistance mutations</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Percentage of participants with virological failure and new resistance mutations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New HIV-1 drug resistance mutations</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Profile of new HIV-1 drug resistance mutations observed in participants with virological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO stage 3-4 morbidity</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Incidence of WHO stage 3-4 morbidity ( AIDS events and non AIDS severe morbidity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANRS grade 3-4 overall morbidity</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Incidence of ANRS grade 3-4 overall morbidity (toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANRS grade 3-4 renal morbidity</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Incidence of ANRS grade 3-4 renal morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANRS grade 3-4 neurologic morbidity</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Incidence of ANRS grade 3-4 neurologic morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANRS grade 3-4 hepatic morbidity</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Incidence of ANRS grade 3-4 hepatic morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of creatinine clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 1,2,3 or 4 renal disorders</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of the percentage of patients with grade 1,2,3 or 4 renal disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 1,2,3 or 4 hepatic liver disorders or abnormalities</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of the percentage of patients with grade 1,2,3 or 4 hepatic liver disorders or abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 1,2,3 or 4 CNS disorders</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of the percentage of patients with grade 1,2,3 or 4 CNS disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of bone mineral density measured using CT bone density scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment using a self-questionnaire</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of adherence to treatments measured using a self-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of quality of life measured using the ProQOL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Evolution of symptoms using the &quot;symptoms experienced&quot; questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARV drug plasma concentrations in participants with treatment failure</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>ARV drug plasma concentrations in participants with treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Switched back to triple therapy</measure>
    <time_frame>Between Day 0 and Week 96</time_frame>
    <description>Percentage of patients on dual therapy who switched back to triple therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of the 3 ARV strategies</measure>
    <time_frame>Week 96</time_frame>
    <description>Cost-effectiveness of the 3 ARV strategies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Arm 1 : Dual maintenance therapy DTG+3TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 : Dual maintenance therapy ATV/r+3TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 : Reference triple therapy TDF+3TC+EFV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir</intervention_name>
    <description>One daily tablet (50mg) during 96 weeks</description>
    <arm_group_label>Arm 1 : Dual maintenance therapy DTG+3TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir boosted with ritonavir</intervention_name>
    <description>One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks</description>
    <arm_group_label>Arm 2 : Dual maintenance therapy ATV/r+3TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir + lamivudine +efavirenz</intervention_name>
    <description>One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks</description>
    <arm_group_label>Arm 3 : Reference triple therapy TDF+3TC+EFV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>One daily tablet (300mg) during 96 weeks</description>
    <arm_group_label>Arm 1 : Dual maintenance therapy DTG+3TC</arm_group_label>
    <arm_group_label>Arm 2 : Dual maintenance therapy ATV/r+3TC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  Age of legal majority

          -  CD4 &gt; 200 cells/mm3 at pre-inclusion

          -  On stable first-line ART with TDF+XTC+EFV for at least 2 years.

          -  Absence of past history of virological failure (viral load above the threshold
             corresponding to the test used); two blips between 50 and 200 copies/ml are allowed.

          -  At least 2 consecutive HIV-1 RNA &lt; 50 copies/ml within past 2 years, including HIV-1
             RNA at pre-inclusion

          -  Women with pregnancy potential are required to use an effective contraceptive method
             throughout the study follow up.

          -  Signed informed consent

        Exclusion Criteria:

          -  HIV-2 infection or HIV-1+2 infection

          -  CD4 nadir &lt;100 cells/mm3

          -  Chronic Hepatitis B (HBs Ag positive in the pre-inclusion balance)

          -  Ongoing active Tuberculosis

          -  Ongoing severe opportunistic infection

          -  Ongoing chemotherapy or immunotherapy

          -  Grade &gt; 2 hemoglobin, neutrophil or platelet disorder

          -  ALT≥ 3 times the upper limit of normal value

          -  Creatinine clearance &lt; 50 ml/min (CKD-EPI)

          -  Allergy to a trial drugs or drug component

          -  Ongoing pregnancy or Refusal of contraception

          -  Patient at risk of non-compliance

          -  Ongoing treatment with a drug that should not be associated with one of the drugs used
             in the study (cf appendix E page 77)

          -  Any symptoms or biological findings suggestive of a systemic disorder (renal, hepatic,
             cardiovascular, pulmonary) or other medical conditions that may interfere with the
             interpretation of test results or jeopardize the health of patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge P. Eholié, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Landman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Médecine et d'Epidémiologie Appliquée - Hôpital Bichat Claude Bernard, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Anglaret, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inserm 1219, Université de Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Marie Girard, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Infectious Diseases Department, University Hospital Saint Antoine, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fadiga Fatoumata, MD</last_name>
    <phone>+225 21755960</phone>
    <email>fatoumata.fadiga@pacci.ci</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raoul Moh, MD, PhD</last_name>
    <phone>+225 21755960</phone>
    <email>raoul.moh@pacci.ci</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital de jour, Service des maladies infectieuses, CHU Sourô Sanou</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <contact>
      <last_name>Armel Poda, MD, Pr</last_name>
      <phone>+22620983758</phone>
      <email>armelpoda@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jacques Zoungrana, MD</last_name>
      <phone>+22620983758</phone>
      <email>zojacques@yahoo.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service de médecine interne, CHU Yalgado Ouédraogo</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <contact>
      <last_name>Youssef Joseph Drabo, MD,Pr</last_name>
      <phone>+22670212156</phone>
      <email>yjdrabo@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ismael Diallo, MD</last_name>
      <phone>+22670249814</phone>
      <email>illah_diallo@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses, Hôpital du jour, Hôpital Central</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles Kouanfack, MD</last_name>
      <phone>+237699950743</phone>
      <email>charleskouanfack@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Prise en Charge et de Formation (CePReF), Association ACONDA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <contact>
      <last_name>Eugène Messou, MD,PHD</last_name>
      <phone>+22523462551</phone>
      <email>messou_eugene@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <contact>
      <last_name>Serge Paul Eholié, MD,Pr</last_name>
      <phone>+22521755960</phone>
      <email>sergeholie@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eboi Ehui, MD,Pr</last_name>
      <phone>+22577192705</phone>
      <email>docehui@yahoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Cameroon</country>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <link>
    <url>http://anrs.fr/</url>
    <description>Sponsor site</description>
  </link>
  <link>
    <url>http://www.mereva.net/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Africa</keyword>
  <keyword>Antiretroviral Treatment</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Adults</keyword>
  <keyword>Dual maintenance therapy</keyword>
  <keyword>Dolutegravir</keyword>
  <keyword>Atazanavir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

